Ardea Biosciences (RDEA) Inactive 10-Q2008 Q2 Quarterly report

Filed: 14 Aug 08, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: Agent, analogy, anticancer, AU, authoritative, background, barrier, buy, cancellation, cancelled, category, certainty, characterization, charge, charged, choose, commodity, comprised, Concurrent, corroborated, defer, deferral, deferred, delivered, derecognition, dividing, Emerging, emtricitabine, England, EPS, ESPP, examination, exit, factoring, FAS, forward, FSP, full, fully, genetic, Gilead, hierarchy, hourly, identical, Immunodeficiency, indirectly, ingredient, inhibit, largest, line, literature, marked, metabolite, MTD, municipal, nominated, nongovernmental, Nonrefundable, orderly, Oversight, partner, pertain, pharmacodynamic, pill, pose, prematurely, prodrug, profile, progression, proxy, rational, reclassified, reproductive, retrospective, salary, satisfaction, sector, significantin, synergy, table, Task, taxation, tenant, tenofovir, threshold, toxicity, transfer, Truvada, tumor, turn, unobservable, unrealized, unutilized, Verenium, vitro

Removed: agree, allocated, applicable, arising, assumed, assuming, attributable, August, avoid, award, aware, bear, broader, component, consecutive, contemplated, convert, convertible, deemed, detailed, devoted, discontinued, duration, economic, equivalent, excluded, forced, forecast, fourth, Global, Hickey, Hill, immaterial, implementing, indefinite, indemnification, indemnify, indemnity, insuring, integral, investing, invoiced, Iseganan, jurisdiction, Lafayette, measured, monitoring, nasdaq, past, peptide, periodically, pneumonia, prevention, profit, regular, remained, remaining, representing, restructuring, speculative, Summary, unvested, VAP, yield

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

RDEA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Each of the undersigned, in his capacity as Chief Executive Officer and Chief Financial Officer, respectively, of Ardea Biosciences, Inc. (the “Registrant”), hereby certifies, for purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

	•		the Quarterly Report of the Registrant on Form 10-Q for the quarter ended June 30, 2008 (the “Report”), which accompanies this certification, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	•		the information contained in the Report fairly presents, in all material respects, the financial condition of the Registrant at the end of such quarter and the results of operations of the Registrant for such quarter.

Dated: August 14, 2008



	/s/ Barry D. Quart
	Barry D. Quart, Pharm.D.
	President and Chief Executive Officer


	/s/ John W. Beck
	John W. Beck, C.P.A.
	Senior Vice President, Finance and Operations and Chief Financial Officer

This certification accompanies the Report to which it relates, is not deemed to be filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Ardea Biosciences, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.

Note:

A signed original of this written statement required by Section 906 has been provided to Ardea Biosciences, Inc. and will be retained by Ardea Biosciences, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.